RNAi Therapeutics and Technology Market Drivers from Chronic Genetic and Infectious Diseases

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "RNAi Therapeutics and Technology Market by Type (Small interfering RNA (siRNA), MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Infectious Diseases, Renal Diseases, Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the RNAi Therapeutics and Technology Market is valued at USD 1.6 Bn in 2023, and it is expected to reach USD 5.28 Bn by the year 2031, with a CAGR of 16.0% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2508

RNA interference (RNAi) is a highly sophisticated biological mechanism that governs gene regulation through sequence-specific gene silencing. This intrinsic cellular process has facilitated the development of RNAi-based therapeutics, an innovative class of treatments that utilize the cell's natural gene-silencing machinery to modulate gene expression with precision. These therapeutics are experiencing increasing adoption within biomedical research and development due to their broad applicability across diverse medical conditions, including oncology, metabolic disorders, and chronic diseases.

RNAi therapies offer a targeted approach to disease management by selectively inhibiting the expression of pathogenic genes through endogenous cellular pathways. This therapeutic category includes modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and microRNAs (miRNA), each employing distinct mechanisms to regulate gene activity, influence protein synthesis, and suppress disease-associated gene expression. The ability to precisely control gene expression positions RNAi-based therapeutics as a transformative platform in modern medicine, with significant potential to address complex and previously intractable conditions.

List of Prominent Players in the RNAi Therapeutics and Technology:
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma
• Dicerna Pharmaceuticals (Novo Nordisk A/S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Glaxosmithkline Plc.
• Ionis Pharmaceuticals (U.S.)
• Moderna, Inc.
• Olix Pharmaceuticals, Inc.
• Quark Software Inc. (U.S.)
• Rexahn Pharmaceuticals, Inc.
• Sanofi
• Silence Therapeutics
• Thermo Fisher Scientific Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics: RNA Interference (RNAi) Therapeutics
Drivers
The global RNA interference (RNAi) therapeutics market is experiencing substantial growth, primarily driven by the increasing prevalence of chronic and genetic disorders such as cancer, cardiovascular diseases, diabetes, tuberculosis, and HIV/AIDS. RNAi-based treatments offer significant potential for managing a wide array of chronic, rare, and hereditary conditions. According to the World Health Organization (WHO), cardiovascular diseases account for approximately 17.9 million deaths annually, followed by cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2 million).

The rising demand for innovative, targeted therapies is accelerating the adoption of RNAi therapeutics, which are becoming integral to personalized medicine and precision healthcare. Furthermore, advancements in high-throughput technologies that identify disease-specific molecular alterations are expanding RNAi applications in oncology diagnostics and targeted therapy, reinforcing the sector's focus on precision medicine.

Challenges
Despite their therapeutic promise, RNAi therapeutics face significant technical and regulatory challenges, particularly related to drug delivery. RNA molecules are inherently unstable and susceptible to rapid degradation by RNases, while their negative charge impedes efficient cellular uptake across hydrophobic cytoplasmic membranes.

Additionally, exogenous RNA can trigger immune responses, potentially reducing efficacy and increasing cytotoxicity. Large-scale manufacturing remains complex, resource-intensive, and difficult to standardize, creating obstacles for production scalability and consistent quality. These technical and regulatory constraints continue to influence clinical development timelines and market accessibility.

Regional Trends
North America, led by the United States, dominates the global RNAi therapeutics market due to the high prevalence of chronic and genetic diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Approximately 40% of U.S. adults are affected by multiple chronic illnesses, highlighting the demand for RNAi-based interventions. Robust investment from pharmaceutical companies, government agencies, and private capital is supporting research, development, and commercialization efforts in this field. The region's well-established regulatory environment, exemplified by the U.S. Food and Drug Administration (FDA), facilitates streamlined evaluation and approval of RNAi therapies, reinforcing North America's leadership position in the global market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2508

Recent Developments:
• In April 2024, Medison Pharma and Alnylam Pharmaceuticals, Inc. expanded their partnership to include selected markets in LATAM, APAC, and additional international markets, in addition to Central & Eastern Europe and Israel. This collaboration will allow companies to expand their footprint and provide the advantages of Alnylam's innovative RNAi treatments to patients in more APAC and LATAM regions.
• In November 2021, Arrowhead Pharmaceuticals linked an exclusive license deal with GlaxoSmithKline (GSK) for their experimental RNA interference (RNAi) therapeutic, ARO-HSD. GSK will lead the development and commercialization of ARO-HSD for treating nonalcoholic steatohepatitis (NASH). ARO-HSD targets HSD17B13 and holds promise as a therapy for both alcohol-related and nonalcohol-associated liver diseases, including NASH.

Segmentation of RNAi Therapeutics and Technology Market-
By Type
• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
By Application
• Genetic Disorders
• Oncology
• Neurodegenerative Disorders
• Infectious Diseases
• Renal Diseases
• Others
By Route of Administration
• Intradermal Injections
• Pulmonary Delivery
• Intravenous Injections
By End-User
• Diagnostic Laboratories
• Research and Academic Laboratories
• Hospitals
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

View Overview Report: https://www.insightaceanalytic.com/report/rnai-therapeutics-and-technology-market/2508

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.